New combo aims to spare bladder in aggressive cancer without removing the organ
NCT ID NCT07279597
First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 23 times
Summary
This study tests whether a mix of immunotherapy (toripalimab), targeted therapy (RC48-ADC), and radiation can help people with HER2-positive muscle-invasive bladder cancer keep their bladder after initial chemotherapy. About 45 adults with stage T2-T4aN0M0 disease will receive the treatment and be followed for response. The goal is to see if the cancer disappears completely without needing bladder removal.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.